Clinical Trial Update: Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating paroxetine-mediated GRK2 inhibition to reduce cardiac remodeling after acute myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Remodeling
• Myocardial Infarction

Drugs mentioned

• Paroxetine-mediated GRK2 inhibition (investigational approach)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Cardiac Remodeling, Myocardial Infarction | Phase 2 | Status: COMPLETED